Remicade Biosimilar CT-P13 Found Safe, Effective for IBD Treatment in Italian Study

Remicade Biosimilar CT-P13 Found Safe, Effective for IBD Treatment in Italian Study
CT-P13, a biosimilar of Remicade (infliximab), is safe and effective for the treatment of inflammatory bowel disease (IBD), a study suggests. The study, "Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers," was published in Annals of Gastroenterology. Remicade works by blocking tumor necrosis factor alpha (TNFα), a signal molecule that drives inflammation. The medicine itself is an antibody, which puts it in a class of therapeutics called biologics — essentially, medications made with the use of living cells. These are unlike other medicines that can be chemically synthesized. Biologics, unsurprisingly, can be pretty expensive, which is where biosimilars come in. Biosimilars are basically the generic drug equivalent of biological medicines. They are intended to be structurally similar to biologics and have the same effect. However, by offering competition to brand-name biologics, biosimilars can drive down costs for patients. This study examined the safety and efficacy of a biosimilar of Remicade, called CT-P13, which is made by Celltrion Healthcare for the treatment of IBD. Researchers reviewed medical records for IBD patients — 96 with
Subscribe or to access all post and page content.